NUROFEN PLUS

Ülke: İsrail

Dil: İngilizce

Kaynak: Ministry of Health

Aktif bileşen:

CODEINE AS HEMIHYDRATE; IBUPROFEN

Mevcut itibaren:

RECKITT BENCKISER (NEAR EAST) LTD

ATC kodu:

M01AE51

Farmasötik formu:

TABLETS

Kompozisyon:

IBUPROFEN 200 MG; CODEINE AS HEMIHYDRATE 10 MG

Uygulama yolu:

PER OS

Reçete türü:

Not required

Tarafından üretildi:

RECKITT BENCKISER HEALTHCARE INTERNATIONAL LTD, UK

Terapötik grubu:

IBUPROFEN, COMBINATIONS

Terapötik alanı:

IBUPROFEN, COMBINATIONS

Terapötik endikasyonlar:

For short term use for the relief of acute (short lasting) moderate pain, such as rheumatic pain (arthritis), muscular pain, backaches, neuralgia, migraine, headache, dental pain and menstrual pain.

Yetkilendirme tarihi:

2015-01-31

Ürün özellikleri

NUROFEN PLUS Tab 25. 12. 2005, RH
"
ע עבקנ הז ןולע טמרופ
"
רשואו קדבנ ונכותו תואירבה דרשמ י
."
“This leaflet format has been determined by the Ministry of Health
and the content thereof has been
checked and approved.”
NUROFEN
® PLUS
TABLETS
COMPOSITION
Each tablet contains:
_Active Ingredient _
Ibuprofen
200
mg
Codeine phosphate hemihydrate 12.8 mg
(equivalent to codeine 10 mg)
_Other Ingredients _
Cellulose, microcrystalline, sodium starch glycollate (
_from potato starch_
), starch
pregelatinised (
_from maize, potato, or rice starch_
), hypromellose (hydroxypropylmethyl
cellulose), titanium dioxide (E 171), talc
PHARMACOLOGICAL PARTICULARS
_Pharmacodynamic Properties _
Ibuprofen is an analgesic which acts peripherally, inhibiting
prostaglandin synthesis
and the action of chemical mediators of pain. Codeine is a narcotic
analgesic acting
on central opiate receptors, although its pharmacological effects are
thought to be
due largely to its biotransformation to morphine.
The combination of a well tolerated peripheral analgesic with a
centrally acting
analgesic provides optimum pain relief with a lower potential for
producing side-
effects.
_Pharmacokinetic Properties _
The elimination half-life of both ibuprofen and codeine is
approximately three hours,
and both drugs are given three to fours times daily. The combination
of the two
drugs is therefore appropriate from a pharmacokinetic viewpoint; the
tablet exhibits
normal release characteristics for both active substances.
INDICATIONS
For the relief of pain in such conditions as: rheumatic and muscular
pain, backache,
neuralgia, migraine, headache, dental pain, dysmenorrhoea,
feverishness, symptoms
of colds and influenza.
CONTRAINDICATIONS
Known hypersensitivity to the drug or to any ingredient of the
preparation.
Patients with a history of, or existing peptic ulceration.
Patients with severe hepatic failure, severe renal failure, severe
heart failure.
Previous allergic reaction to any other pain reliever / fever re